Out to prove the next big I/O target, Immunitas’ chief dealmaker steps up to CEO role November 16, 2021
Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer September 9, 2021
Touting CD161 as a Test Case for Single-Cell Tech, Longwood-backed Immunitas Bags $58M for Next-Gen I/O Work August 19, 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases August 18, 2021
Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology February 18, 2021
